McKesson Corporation stock (US58155Q1031): Q4 earnings beat with raised FY27 guidance

McKesson Corporation reported Q4 EPS of $11.69, beating estimates by $0.13, while revenue hit $96.3B. Shares dipped post-earnings, but analysts raised forecasts amid upbeat outlook.

McKesson Corporation released its fiscal Q4 2026 earnings on May 7, 2026, posting adjusted EPS of $11.69, surpassing analyst consensus of $11.56 by $0.13, MarketBeat as of 05/08/2026. Quarterly revenue climbed 6.0% year-over-year to $96.30 billion, missing expectations of $101.35 billion. The company raised its fiscal 2027 EPS guidance to $43.80-$44.60, signaling confidence despite revenue softness. Full-year revenue reached $403 billion, with statutory EPS of $38.38 topping forecasts by 9.0%, Simply Wall St as of recent. Shares fell 8.9% to $736 in the week following results, trading at $734.93 on May 8, 2026 on NYSE.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: McKesson Corporation
• Sector/industry: Healthcare / Pharmaceutical distribution
• Headquarters/country: United States
• Core markets: North America
• Key revenue drivers: Prescription drug distribution, medical supplies
• Home exchange/listing venue: NYSE (MCK)
• Trading currency: USD

McKesson Corporation: core business model

McKesson Corporation ranks among the largest pharmaceutical distributors in North America, supplying drugs and medical supplies to pharmacies, hospitals, and health systems. Its U.S. Pharmaceutical segment, the primary revenue engine, handles distribution of generic and branded medications, generating the bulk of sales through high-volume logistics. The company also operates a Medical-Surgical Solutions unit focused on provider solutions and a Prescription Technology Solutions division offering tech-enabled services like automation and data analytics.

This model benefits from scale in a fragmented industry, with McKesson leveraging its vast network to negotiate favorable terms with manufacturers. For U.S. investors, McKesson's NYSE listing and exposure to the $600 billion-plus U.S. drug distribution market underscore its relevance amid rising healthcare spending.

Main revenue and product drivers for McKesson Corporation

Prescription drug distribution drives over 80% of revenue, with key growth from specialty pharmaceuticals like oncology and biologics. Fiscal 2026 full-year revenue of $403 billion reflected steady demand, per results published May 7, 2026. Medical supplies and technology services contribute smaller but higher-margin segments, bolstered by acquisitions and partnerships.

U.S. market dynamics, including pharmacy benefit manager shifts and biosimilar uptake, directly impact performance. McKesson's Q4 revenue growth of 6.0% year-over-year highlights resilience in core distribution amid payer pressures.

Industry trends and competitive position

The U.S. pharmaceutical wholesale sector faces margin compression from drug pricing reforms but benefits from volume growth in generics and specialties. McKesson competes with AmerisourceBergen and Cardinal Health, holding a leading ~25% market share via efficient supply chain tech. Recent earnings upgrades by analysts reflect optimism on earnings trajectory over revenue.

Why McKesson Corporation matters for US investors

As a NYSE-listed staple in healthcare logistics, McKesson offers U.S. investors exposure to essential services tied to America's aging population and chronic disease prevalence. Its role in the supply chain positions it as a defensive play with growth from digital health adoption.

Conclusion

McKesson Corporation's Q4 beat and raised FY27 guidance highlight earnings strength despite revenue misses, with analysts lifting EPS forecasts to $41.77 for 2027. Shares faced post-earnings pressure, trading around $735 on NYSE, reflecting market rotation. For U.S. investors tracking healthcare distribution, the company's scale and outlook remain key focal points amid sector evolution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.